Kelly Mckelvey
Sydney Neuro-Oncology Group / Sydney Vital Inflamm
Oncology
Bill Walsh Translational Cancer Research Laboratory
Australia
Biography
Dr Kelly McKelvey joined the Sydney Neuro-Oncology Group (SNOG) and Sydney Vital, Bill Walsh Translational Cancer Research Laboratory at the Sydney Medical School Northern, University of Sydney in May 2017.
Research Interest
My work investigates the interactions between brain cancer cells and the patients immune system, during cancer development and following chemo- and/or radiation therapy. In Australia one individual is diagnosed with brain cancer every 5 hours. Despite improvements in survival for other cancers (e.g. ovarian, prostate, breast), the average survival time for a patient with brain cancer remains 10-14 months. It is recognised that the patient immune system supports brain cancer growth and relapse. Following therapy (chemo or radiation) the immune system also contributes to side effects and pooroer patient outcomes. However, the specific mechanisms are poorly understood. My research provides greater understanding of the interactions of cancer and patient inflammatory systems during cancer growth, and therapy. The outcomes will support early diagnosis, achieve brain cancer remission, and alleviate the detrimental systemic inflammatory response which results in poorer patient outcomes.
Publications
-
Exosomes: Mechanisms of Uptake.
-
Embryonic/fetal mortality and intrauterine growth restriction is not exclusive to the CBA/J sub-strain in the CBA / DBA model.
-
Aberrant levels of natural IgM antibodies in osteoarthritis and rheumatoid arthritis patients in comparison to healthy controls.
